Meanwhile, LEF1 has been identified as a useful diagnostic marker for the development, metastases, and poor prognoses in several cancers, including chronic lymphocytic leukemia (Menter et al, 2017), breast cancer (Gilles et al, 2003), liver cancer (Singhi et al, 2014), prostate cancer (Yang et al, 2006). This evidence concerns the gene LEF1 and B-cell chronic lymphocytic leukemia.